Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2011-07-12
2011-07-12
Wilson, James O (Department: 1624)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C544S127000, C544S333000, C544S362000, C546S121000, C546S268100, C548S375100, C548S503000
Reexamination Certificate
active
07977352
ABSTRACT:
Novel triazolopyridine compounds are disclosed that have a formula represented by the following:The compounds may be prepared as pharmaceutical compositions, and may be used for the prevention and treatment of a variety of conditions in mammals including humans, including by way of non-limiting example, ECM degradation, joint degradation and/or inflammation, and others.
REFERENCES:
patent: 6919341 (2005-07-01), Paruch et al.
patent: 7576085 (2009-08-01), Guzi et al.
patent: 2007/0117804 (2007-05-01), Zhao et al.
patent: 2009/0048245 (2009-02-01), Edwards et al.
patent: 0117999 (2001-03-01), None
patent: 2004014908 (2004-02-01), None
patent: 2005070927 (2005-08-01), None
patent: 2006004702 (2006-01-01), None
patent: 2007131991 (2007-11-01), None
patent: 2007138072 (2007-12-01), None
Jordan, V. C. Nature Reviews: Drug Discovery, 2, 2003, p. 205.
Dörwald, F. Zaragoza. Side Reactions in Organic Synthesis: A Guide to Successful Synthesis Design, Weinheim: Wiley-VCH Verlag GmbH & Co. KGaA, 2005, Preface.
Vippagunta, et al. Advanced Drug Delivery Reviews, 48, 2001, 18.
Wolff, Manfred E., Ed. Burger's Medicinal Chemistry and Drug Discovery—Fifth Edition, New York: John Wiley & Sons, 1996, vol. 1, 975-976.
Andreakos E, et al. (2003). Arthritis Rheum. 48: 1901-12.“Heterogeneous requirement of IkB kinase 2 for inflammatory cytokine and matrix metalloproteinase production in RA”.
Blonska M. et al. (2005) J. Biol. Chem. 280: 43056-43063. “TAK1 Is Recruited to the Tumor Necrosis Factor-(TNF-) Receptor 1 Complex in a Receptor-interacting Protein (RIP) . . . ” .
Boutros M. at al. (2002) Dev. Cell 3(5): 711-722. “Sequential activation of signaling pathways during innate immune responses in Drosophila.”.
Choy EH, Panayi GS. (2001). N Engl J Med. 344: 907-16. “Cytokine pathways and joint inflammation in rheumatoid arthritis.”
Coussens LM, et al. (2002). Science 295: 2387-92. “Matrix metalloproteinase inhibitors and cancer: trials and tribulations.”
Creemers EE, et al. (2001). Circ Res. 2001 89:201-10. “Matrix metalloproteinase inhibition after myocardial infarction.”
Cunnane G, et al. (2001). Arthritis Rheum 44: 2263-74. “Early joint erosions and serum levels of matrix metalloproteinase 1, matrix metalloproteinase 3, . . . ”.
Dong W. et al. (2006). J. Biol. Chem. 281: 26029-26040. The IRAK-1-BCL10-MALT1-TRAF6-TAK1 Cascade Mediates Signaling to NF-B from Toll-like receptor 4.
Edwards J. C.W. et al. (2004) N Engl J Med. 350:2572-2581. “Efficacy of B-cell-targeted therapy with rituximab in patients with RA.”
Firestein GS. (2003). Nature. 423:356-61. “Evolving concepts of rheumatoid arthritis.”
Gapski R, et al. (2004). J Periodontol. 75:441-52. “Effect of Systemic Matrix Metalloproteinase Inhibition on Periodontal Wound Repair: A Proof of Concept Trial.”
Gomez-Reino JJ et al. (2003). Arthritis Rheum. 48: 2122-7. “Treatment of rheumatoid arthritis with tumor necrosis factor inhibitors . . . ”.
Huang H. et al. (2006). Cell Death Differ. 13:1879-1891. “Osteoclast differentiation requires TAK1 and MKK6 for NFATc1 induction and NF-κB transactivation by RANKL”.
Irie T et al. (2000) FEBS Lett. 467:160-164. “TAK1 mediates an activation signal from toll-like receptor(s) to nuclear factor-κB in lipopolysaccharide-stimulated macrophages.”
Klatt AR et al. (2006) Biomedicine&Pharmacotherapy 60:55-61. “TAK1 downregulation reduces IL-1β induced expression of MMP13, MMP1 and TNF-alpha.”
Kremer JM. et al. (2003) N Engl J Med. 349:1907-1915. “Treatment of RA by selective inhibition of T-cell activation with fusion protein CTLA4Ig.”
Lee DM, Weinblatt ME (2001). Lancet. 358: 903-11. “Rheumatoid arthritis.”
Muzikami J. et al. (2002) Mol. Cell Biol. 22: 992-1000. “Receptor Activator of NF-B Ligand (RANKL) Activates TAK1 Mitogen-Activated Protein Kinase . . . ”.
New L. et al. (2003) Mol Biol Cell. 14(6):2603-16. “Regulation of PRAK subcellular location by p38 MAP kinases . . . ”.
Ninomiya-Tsuji J. et al. (1999). Nature 398: 252-256. “The kinase TAK1 can activate the NIK-IκB as well as the MAP kinase cascade in the IL-1 signalling pathway.”
O'Dell JR et al. (2002). Arthritis Rheum. 46:1164-70. “Treatment of RA with methotrexate and hydroxychloroquine, methotrexate and sulfasalazine, . . . ”.
O'Dell JR. (2004) N Engl J Med. 350(25):2591-602. “Therapeutic strategies for rheumatoid arthritis.”
Reif S. et al. (2005) Digestion. 71:124-130. “Matrix metalloproteinases 2 and 9 are markers of inflammation but not of the degree of fibrosis in chornic hepatitis C”.
Rosenberg GA. (2002). Glia. 39:279-91. “Matrix metalloproteinases in neuroinflammation.”
Sakurai H. et al. (1999). J. Biol. Chem. 274: 10641-10648. “Functional Interactions of Transforming Growth Factor—activated Kinase 1 with IB Kinases to Stimulate NF-B . . . ”.
Sato S. et al. (2005) Nat. Immunol. 6: 1087-1095. “Essential function for the kinase TAK1 in innate and adaptive immune responses”.
Schanstra JP. et al. (2002) J Clin Invest. 110:371-9. “In vivo bradykinin B2 receptor activation reduces renal fibrosis.”
Shi Y et al. (2003). Mol Cell Biol. 23:7732-41. “Elimination of protein kinase MK5/PRAK activity by targeted homologous recombination.”
Shibuya H. et al. (1998). EMBO J. 17: 1019-1028. “Role of TAK1 and TAB1 in BMP signaling in early Xenopus development.”
Shim JH. et al. (2005) Genes Dev. 19:2668-2681. “TAK1, but not TAB1 or TAB2, plays an essential role in multiple signaling pathways in vivo.”
Smolen JS, Steiner G. (2003). Nat Rev Drug Discov. 2: 473-88. “Therapeutic strategies for rheumatoid arthritis.”
St. Clair E.W. et al. (2004). Arthritis Rheum. 50 :3432-43.Combination of infliximab and methotrexate therapy for early rheumatoid arthritis: a randomized, controlled trial.
Suzuki et al. (2004). Treat Respir Med. 3:17-27. “Matrix metalloproteinases in the pathogenesis of asthma and COPD.”
Vidal S. et al. (2001). Genes & Dev. 15: 1900-1912. “Mutations in the Drosophila dTAK1 gene reveal a conserved function for MAPKKKs . . . ”.
Wan YY. et al. (2006). Nat. Immunol. 7: 851-858. “The kinase TAK1 integrates antigen and cytokine receptor signaling for T cell development, survival and function.”
Yamaguchi K et al. (1995). Science 270: 2008-2011. “Identification of a Member of the MAPKKK Family as a Potential Mediator of TGF-Signal Transduction.”
Yang YH et al. (2004). Arthritis Rheum. 50:976-84.“Modulation of inflammation and response to dexamethasone by Annexin 1 in antigen-induced arthritis.”
Andrews Martin James Inglis
Birault Veronique
Burritt Andrew
Edwards Paul John
Kroll Friedrich Erich Karl
Galapagos NV
Klauber & Jackson LLC
Willis Douglas M
Wilson James O
LandOfFree
Triazolopyridine compounds useful for the treatment of... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Triazolopyridine compounds useful for the treatment of..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Triazolopyridine compounds useful for the treatment of... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2640757